P2K (U.S. name SB-01), a candidate therapy for degenerative disc disease developed by Ensol Biosciences and transferred to U.S.-based Spine Biopharma, was mentioned on a global medical podcast as a future technology for spine treatment.
According to the industry on the 11th, Dr. Jeffrey Roh, a spine surgeon and founder of Excel Health, appeared on The Loop Way, which aired on the 8th, and cited SB-01 as one of three key peptides he is watching most closely.
Peptides are biomolecules composed of linked amino acids. Peptide therapeutics act by leveraging these structures to bind to specific cell receptors, modulating signal transmission and altering physiological processes such as inflammation, metabolism, and regeneration.
On the program themed The Future of Spine Surgery, Roh explained, "Spine surgery is shifting from traditional open procedures to minimally invasive methods, and in the future it could expand into needle-based biological therapies."
In particular, regarding peptide-based treatment approaches, he said, "When therapies emerge that can modulate disc degeneration and improve inflammatory responses, the paradigm of spine disease treatment could shift toward regeneration." He also noted the possibility that this "needle-based fundamental regeneration therapy" approach could evolve into the standard of care.
Ensol Biosciences said, "This video shows that our biomimetic, signal pathway–selective modulation technology is gaining attention as a regenerative medicine–based treatment approach in global clinical discussions."
Kim Hae-jin, CEO of Ensol Biosciences, said, "SB-01 is a candidate under validation as an injection-based treatment for disc disease," adding, "We will continue global technology development and clinical expansion." Kim said, "SB-01 (P2K) is expected to have development potential as a new treatment option that can treat patients with spinal diseases worldwide without surgery."